Current Report Filing (8-k)
August 03 2017 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 1, 2017
ZOGENIX, INC.
(Exact
Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-34962
|
|
20-5300780
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
5858 Horton Street, #455, Emeryville, CA
|
|
94608
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (510)
550-8300
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 1.02
|
Termination of a Material Definitive Agreement.
|
On August 1, 2017, Zogenix, Inc., a Delaware
corporation (the Company) and Durect Corporation, a Delaware corporation (
Durect
) entered into a Termination Agreement (the
Termination Agreement
), which terminates the Development and License
Agreement dated July 11, 2011, by and between the Company and Durect (as amended, the
Durect Agreement
). Under the Durect Agreement, Durect granted to the Company worldwide development and commercialization rights to Relday.
Relday is an investigational long-acting formulation of risperidone, an atypical anti-psychotic agent.
Under the Termination Agreement, the Companys
development and commercialization rights are returned to Durect, and the Company will transfer to Durect all regulatory filings and development information related to Relday.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ZOGENIX, INC.
|
|
|
|
|
Date: August 2, 2017
|
|
|
|
By:
|
|
/s/ Michael P. Smith
|
|
|
|
|
Name:
|
|
Michael P. Smith
|
|
|
|
|
Title:
|
|
Executive Vice President, Chief Financial Officer, Treasurer and Secretary
|
Zogenix (NASDAQ:ZGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zogenix (NASDAQ:ZGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024